ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

INVESTIGATION OF THE TRAITS OF CLINICAL THERAPEUTIC DRUGS IN ELDER PATIENTS OF CHRONIC HEART FAILURE INTRICATED WITH VARIOUS STAGES OF INEFFICIENCY OF KIDNEYS

AUTHORS:

Dr Sara Najam, Dr Ali Hassan, Dr Masooma Rubab

ABSTRACT:

Objective: This research work aimed to investigate the traits of the clinical drugs in elder patients with CHD (Chronic Heart Failure) complexed with various grades of the inefficiency of kidneys. Methodology: The patient with elder age who were admitted from November 2014 to November 2018 in our institute because of chronic heart failure for the very first time were the part of this research work. We carried out the estimation of the GFR (Glomerular Filtration Rate) with the utilization of the study equation of MDRD (Modification of Diet in Renal Disease). We divided the patients into the group with normal function of kidneys, a group with small reduction in the function of kidneys and a group with moderate & severe reduction in the function of kidneys. We carried out the statistical analysis for the comparison of the traits of the clinical drugs for all these groups of the patients. Results: As compared to the group of the patients with normal function of kidneys & group of the slight reduction in renal function, there were less ACEIs & β-blockers utilized in moderate & severe reduction of renal function groups, but there was more use of the diuretics & spironolactone. In comparison with the group of the normal renal function, the rate of use of ACEIs was less while that of diuretics was much high (P<0.050). Conclusion: ACEIs & β-blockers were scarcely employed for the treatment of elderly patients with chronic heart failure complicated with the inefficiency of kidneys but there was frequent utilization of the diuretics & spironolactone. Keywords: ACEIs, CHD, sever, moderate, inefficiency, methodology, diuretics, GFR, modification.

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.